DIA/FDA Oligonucleotide-based Therapeutics 2012: Leveraging Regulators and Industry Knowledge for Fu
|Event Date/Time: Apr 16, 2012||End Date/Time: Apr 18, 2012|
|Abstract Submission Date: Mar 02, 2012|
For the past four years DIA/FDA has convened industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. The 2012 event will continue to address bioinformatics, microRNAs, delivery methods, impurity issues, metabolism, non-clinical assessments in support of drug development and clinical advances in therapeutic targets, trial design and safety. This conference will also incorporate dialogue to address RNA interference technologies and expand clinical pharmacology representation in discussions of the emerging technologies being developed in the field of oligonucleotide-based therapeutics.
â€¢ Chemistry, Manufacturing, and Controls (CMC)
â€¢ Clinical Development
â€¢ Oligonucleotide Safety Working Group Updates